Cell Lysis and Disruption Market Report 2026

The cell lysis and disruption market size has grown strongly in recent years. It will grow from $5.34 billion in 2025 to $5.8 billion in 2026 at a compound annual growth rate (CAGR) of 8.7%. The growth in the historic period can be attributed to expansion of molecular biology research activities, increasing use of recombinant protein production, growth in academic life sciences research, rising adoption of microbial fermentation processes, availability of advanced laboratory instruments.

The cell lysis and disruption market size is expected to see strong growth in the next few years. It will grow to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to increasing demand for biologics manufacturing, rising investments in cell and gene therapy research, expansion of proteomics and genomics studies, growing focus on automation in laboratories, increasing use of high-throughput screening platforms. Major trends in the forecast period include increasing adoption of mechanical cell disruption systems, rising use of high-purity lysis reagents, growing demand for scalable cell processing solutions, expansion of automated sample preparation workflows, enhanced focus on yield and reproducibility.

The increasing emphasis on personalized medicine is expected to drive the growth of the cell lysis and disruption market in the coming years. Personalized medicine is an approach that tailors treatment and care to the unique characteristics of each patient, including their genetics and lifestyle. Demand for personalized medicine is rising due to advances in genomic technologies, which allow for more precise identification of disease-causing genetic variations and enable targeted, more effective therapies. The growing focus on personalized medicine supports the use of cell lysis and disruption, as these processes are crucial for extracting deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and proteins from patient samples, facilitating the molecular analysis needed to develop individualized treatments. For example, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit, and the U.S. Food and Drug Administration (USFDA), 16 new personalized treatments for rare disease patients were approved in 2023, a significant increase from 6 approvals in 2022. Therefore, the rising focus on personalized medicine is boosting the growth of the cell lysis and disruption market.

Key companies in the cell lysis and disruption market are focusing on developing advanced solutions such as single-cell microfluidic platforms to enhance the efficiency and capabilities of single-cell analysis in microbial genomics. A single-cell microfluidic platform is a miniaturized device that isolates, manipulates, and analyzes individual cells by controlling tiny fluid volumes within microchannels, enabling automated, high-throughput single-cell studies. For instance, in January 2024, Atrandi Biosciences Inc., a Lithuania-based biotechnology company, launched its Flux platform along with the Single-Microbe DNA Barcoding Kit. These products use semi-permeable capsule (SPC) technology to efficiently isolate and lyse individual microbial cells while preserving the integrity of downstream reactions. The platform offers high-throughput capabilities, allowing precise microbial genome quantification and DNA sequencing, which are critical for advancing microbial genomics and single-cell research. These solutions streamline workflows, making high-resolution single-cell analysis more accessible and effective for researchers across various scientific fields.

In July 2023, QIAGEN N.V., a Netherlands-based provider of reagents and kits for cell lysis, partnered with Niba Labs to enhance the precision, efficiency, and standardization of molecular diagnostic and drug development processes. This partnership aims to combine their expertise in digital polymerase chain reaction (PCR) assay development and sample testing to offer customized solutions to biopharma companies, optimizing nucleic acid quantification, improving the accuracy and repeatability of viral vector titration, and meeting the growing demand for high-sensitivity analysis in cell and gene therapy applications. Niba Labs is a Slovenia-based biotechnology company specializing in cell and gene therapy analytics.

Major companies operating in the cell lysis and disruption market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company (BD), Agilent Technologies Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Eppendorf AG, Miltenyi Biotec GmbH, Takara Bio Inc., Promega Corporation, New England Biolabs Inc., Covaris LLC, Microfluidics International Corp., Claremont BioSolutions LLC, Qsonica LLC, Zymo Research Corp., BioVision Inc., Beckman Coulter Inc., Sartorius AG, PerkinElmer Inc.

North America was the largest region in the cell lysis and disruption market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell lysis and disruption market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell lysis and disruption market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cell lysis and disruption market by increasing costs of imported homogenizers, sonicators, microfluidizers, specialty enzymes, and laboratory-grade consumables used across research and bioprocessing workflows. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to dependence on imported precision instruments and reagents, while Asia-Pacific faces cost pressure on equipment manufacturing and exports. These tariffs are increasing operational expenses and procurement lead times for laboratories. However, they are also encouraging localized manufacturing of laboratory instruments, regional reagent production, and supplier diversification to strengthen supply chain resilience.

The cell lysis and disruption market research report is one of a series of new reports that provides cell lysis and disruption market statistics, including cell lysis and disruption industry global market size, regional shares, competitors with a cell lysis and disruption market share, detailed cell lysis and disruption market segments, market trends and opportunities, and any further data you may need to thrive in the cell lysis and disruption industry. This cell lysis and disruption market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell lysis and disruption refer to processes that compromise or break a cell’s membrane, releasing its internal contents. Cell lysis specifically involves breaking the cell membrane or wall using chemical, enzymatic, or biological methods, while cell disruption is a broader term that also includes mechanical techniques, such as sonication, bead milling, or homogenization, as well as non-mechanical approaches often used for tougher cells like bacteria or yeast. While cell lysis is a subset of cell disruption, both processes aim to access intracellular materials for downstream applications in research and biotechnology.

The primary products of cell lysis and disruption include reagents and consumables, as well as instruments. Reagents and consumables consist of chemical substances and single-use materials such as buffers, enzymes, detergents, tubes, and pipette tips, used to lyse cells and extract their internal components for further analysis. These products are applicable to various cell types, including bacterial cells, mammalian cells, plant cells, and yeast, fungi, or algae, and are used for applications such as cell organelle isolation, protein extraction, nucleic acid isolation, and downstream processing. Key end users include pharmaceutical and biotechnology companies, academic and research institutes, and other organizations.

The cell lysis and disruption market consists of revenues earned by entities by providing services such as contract cell lysis services, customized sample preparation services, cell disruption protocol development, analytical testing and validation services related to lysates. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell lysis and disruption market also includes sales of bead-based lysis systems, microfluidizer-based cell disruption systems, and pressure-based cell disruptors. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.